Compare RAYA & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | VTAK |
|---|---|---|
| Founded | 2019 | 2002 |
| Country | China | United States |
| Employees | 360 | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.1M |
| IPO Year | 2022 | 2018 |
| Metric | RAYA | VTAK |
|---|---|---|
| Price | $4.06 | $2.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.1K | ★ 52.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | $730,000.00 |
| Revenue This Year | $20.95 | $822.86 |
| Revenue Next Year | N/A | $168.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.78 | ★ 82.96 |
| 52 Week Low | $3.13 | $1.49 |
| 52 Week High | $736.99 | $15.68 |
| Indicator | RAYA | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 54.17 |
| Support Level | $3.70 | $2.26 |
| Resistance Level | $5.62 | $3.06 |
| Average True Range (ATR) | 0.50 | 0.25 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 56.96 | 62.32 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.